Minerva Neurosciences | NERV - Umsatzkosten

Aktienkurs
5.54
Täglich Wechseln
0.03 0.54%
Monatlich
-29.34%
Jährlich
253.38%
Q2 Prognose
5.36




Umsatzkosten Veränderung Datum
Acadia Pharmaceuticals USD 26.22M 4.58M 2025-12
Adma Biologics USD 50.4M 8.24M 2025-12
ALKERMES USD 46.21M 5.38M 2025-12
AstraZeneca USD 3.27B 471M 2025-12
BioCryst Pharmaceuticals USD 9.52M 7.34M 2025-12
Bristol-Myers Squibb USD 4.92B 657M 2025-12
Cipla INR 29.1B 1.16B 2025-12
Clal Biotechnology ILS 16.49M 2.64M 2022-06
Compugen USD 3.54M 1.89M 2025-12
CSL USD 3.87B 2.08B 2025-12
Eli Lilly USD 3.37B 363.7M 2025-12
Esperion Therapeutics USD 27.85M 13.43M 2025-12
GlaxoSmithKline GBP 2.61B 377M 2025-12
Grifols EUR 1.51B 184.45M 2025-12
Halozyme Therapeutics USD 102.15M 29.14M 2025-12
Ionis Pharmaceuticals USD 8M 5.66M 2025-12
J&J USD 7.97B 689M 2025-12
Merck USD 3.32B 531M 2025-12
Minerva Neurosciences 386K 31K 2024-06
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Novartis USD 3.54B 3M 2025-12
Novavax USD 22.1M 608K 2025-12
Pfizer USD 6.29B 2.12B 2025-12
Roche Holding CHF 8.48B 4.61B 2025-12
Sanofi EUR 4.29B 421M 2025-12
Takeda JPY 401.15B 184.07B 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12